All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-12-12T15:06:15.000Z

Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?

By Emily Smith, Elina Simanovits, Anas Younes
Featured
Anas Younes
Dec 12, 2019
Share:

Bookmark this article

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US. We asked: Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?

Anas Younes discusses the concept of using nanoparticles to deliver BCL-2 family inhibitors, such as venetoclax, or an MCL-1 inhibitor, in order to reduce the toxicity seen when a BCL-2 family inhibitor and MCL-1 inhibitor are administered simultaneously. Providing one of these agents via nanoparticles was shown to reduce toxicity in mouse models, potentially providing a new method of administering multiple agents at the same time.

Could nanoparticles help to deliver BH3 mimetics more effectively in lymphoma?

More about...
Aggressive B-cell lymphomasASH 2019Diffuse large B-cell lymphomaVenetoclax

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

ASCO 2018 | The Highlights 

Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual meeting, Chicago, June 1-5

Aug 1, 2018
Add bookmark

ASCO 2018 | The Highlights 

Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual...

Aug 1, 2018
Add bookmark

Dr. Stephen Robinson | EBMT 2018 | Bridging therapies & novel salvage strategies in DLBCL

Stephen Robinson | EBMT 2018 | Bridging therapies & novel salvage strategies in DLBCL

Mar 26, 2018
Add bookmark

Dr. Stephen Robinson | EBMT 2018 | Bridging therapies & novel salvage strategies in DLBCL

Stephen Robinson | EBMT 2018 | Bridging therapies & novel salvage strategies in DLBCL

Mar 26, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox